Minute dosages of α ν β 3 -targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits Patrick M. Winter * ,1 , Anne H. Schmieder * , Shelton D. Caruthers * ,† , Jeffery L. Keene ‡ , Huiying Zhang * , Samuel A. Wickline * and Gregory M. Lanza * ,1 * Washington University Medical School, St. Louis, Missouri, USA; † Philips Medical Systems, Andover, Massachusetts, USA; and ‡ Kereos, Inc., St. Louis, Missouri, USA 1 Correspondence: Washington University Medical School, Campus Box 8215, 4320 Forest Park Ave., St. Louis, MO 63108, USA. E-mail: P.M.W, patrick@cvu.wustl.edu ; or G.M.L., greg@cvu.wustl.edu Fumagillin suppresses angiogenesis in cancer models and clinical trials, but it is associated with neurotoxicity at systemic doses. In this study, α ν β 3 -targeted fumagillin nanoparticles were used to suppress the neovasculature and inhibit Vx-2 adenocarcinoma development using minute drug doses. Tumor-bearing rabbits were treated on days 6, 9, and 12 postimplantation with α ν β 3 -targeted fumagillin nanoparticles (30 µg/kg), α ν β 3 -targeted nanoparticles without drug, nontargeted fumagillin nanoparticles (30 µg/kg) or saline. On day 16, MRI was performed with α ν β 3 -targeted paramagnetic nanoparticles to quantify tumor size and assess neovascularity. Tumor volume was reduced among rabbits receiving α ν β 3 -targeted fumagillin nanoparticles (470±120 mm 3 ) compared with the three control groups: nontargeted fumagillin nanoparticles (1370±300 mm 3 , P <0.05), α ν β 3 -targeted nanoparticles without drug (1080±180 mm 3 , P <0.05) and saline (980±80 mm 3 , P <0.05). MR molecular imaging of control rabbits (no fumagillin) revealed a predominant peripheral distribution of neovascularity representing 7.2% of the tumor rim volume, which decreased to 2.8% ( P <0.05) with α ν β 3 -targeted fumagillin nanoparticle treatment. Microscopically, the tumor parenchyma tended to show T-cell infiltration after targeted fumagillin treatment, which was not appreciated in control animals. These results suggest that α ν β 3 -targeted fumagillin nanoparticles could provide a safe and effective means to deliver MetAP2 inhibitors alone or in combination with cytotoxic or immunotherapy.—Winter, P. M., Schmieder, A. H., Caruthers, S. D., Keene, J. L., Zhang, H., Wickline, S. A., Lanza, G. M. Minute dosages of α ν β 3 -targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits. Key Words: MRI • cancer • drug delivery • molecular imaging
End of preview. The entire article is 10 pages. To view the full-text, please rent this article to continue.
/lp/fed-of-american-socs-for-experimental-biology/minute-dosages-of-3-targeted-fumagillin-nanoparticles-impair-vx-2-pfi96Wz7LU
Welcome to DeepDyve! Rent Premier Research Articles and Save Up to 90%
Minute dosages of ανβ3-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits
Winter, Patrick M.; Schmieder, Anne H.; Caruthers, Shelton D.; Keene, Jeffery L.; Zhang, Huiying; Wickline, Samuel A.; Lanza, Gregory M.
Follow The FASEB Journal
, Volume 22 (8): 2758
Fed of American Socs for Experimental Biology – Aug 1, 2008
More Info
More Like This Article
View All dataSource[]=actageo&dataSource[]=aspet&dataSource[]=aaos&dataSource[]=aacc&dataSource[]=aacr&dataSource[]=aea&dataSource[]=aip&dataSource[]=ajnr&dataSource[]=ams&dataSource[]=aps_physical&dataSource[]=appi_book&dataSource[]=appi_journal&dataSource[]=apha&dataSource[]=asip&dataSource[]=asm&dataSource[]=asn&dataSource[]=aspb&dataSource[]=avs&dataSource[]=annual_reviews&dataSource[]=arxiv&dataSource[]=acm&dataSource[]=berghahn&dataSource[]=cabi&dataSource[]=clinical_trials&dataSource[]=dailymed&dataSource[]=degruyter&dataSource[]=du_press&dataSource[]=esa&dataSource[]=eu_press&dataSource[]=elsevier&dataSource[]=emerald&dataSource[]=ejtr&dataSource[]=emea&dataSource[]=epo&dataSource[]=faseb&dataSource[]=gsa&dataSource[]=health_affairs&dataSource[]=hindawi&dataSource[]=imanager&dataSource[]=imedpub&dataSource[]=informa_healthcare&dataSource[]=informs&dataSource[]=iop&dataSource[]=iucr&dataSource[]=iospress&dataSource[]=jbjs&dataSource[]=leftcoast&dataSource[]=lu_press&dataSource[]=mesharpe&dataSource[]=mary_ann_liebert&dataSource[]=medline&dataSource[]=mit_press&dataSource[]=nature&dataSource[]=oxford&dataSource[]=pier_professional&dataSource[]=pnas&dataSource[]=portlandpress&dataSource[]=psyc_articles&dataSource[]=psyc_books&dataSource[]=psyc_critiques&dataSource[]=plos_journal&dataSource[]=pubmed_central&dataSource[]=rsna&dataSource[]=rockefeller&dataSource[]=rcn&dataSource[]=ria&dataSource[]=rsc&dataSource[]=sage&dataSource[]=spie&dataSource[]=springer_journal&dataSource[]=springer&dataSource[]=taylor_francis&dataSource[]=aps&dataSource[]=the_scientist&dataSource[]=uc_press&dataSource[]=uspto_abstract&dataSource[]=wiley&dataSource[]=pct
© 2012 DeepDyve, Inc. All rights reserved.
Terms of Service | Privacy Policy
